China (Mainland)
GS-9620 high purity CAS NO.1228585-88-3
- Min.Order: 10 Milligram
- Payment Terms:
- Product Details
Keywords
- GS-9620
- high purity
- Chengdu Henghui Pharm Tec Co. Ltd
Quick Details
- ProName: GS-9620 high purity
- CasNo: 1228585-88-3
- Molecular Formula: 1228585-88-3
- Appearance: white powder
- Application: For laboratory use only- not intended ...
- ProductionCapacity: 1 Kilogram/Month
- Purity: ≥98%
- Storage: room temperature
- LimitNum: 10 Milligram
Superiority
We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.
We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.
We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.
We make our efforts to offer customer innovative, customized, high-quality service.
Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.
Details
| GS-9620 is a potent and selective orally active agonist of Toll-Like Receptor (TLR)7. IC50 & Target: TLR7. In Vitro:GS-9620 rapidly internalizes into cells and preferentially localizes to and signals from endo-lysosomal compartments. To test this hypothesis, the kinetics of cellular uptake of the compound in Daudi cells using tritiated GS-9620 (3H-GS-9620) is measured. The kinetics of 3H-GS-9620 accumulation is rapid, reaching concentration-dependent steady-state equilibrium in approximately thirty minutes. Measured intracellular concentration of 3H-GS-9620 is 5-fold higher than the extracellular concentration of 3H-GS-9620 used to treat cells. Increases in intracellular3H-GS-9620 concentrations are roughly proportional with increasing concentrations of 3H-GS-9620. In Vivo:Single oral doses of GS-9620 at 0.3 and 1 mg/kg in uninfected chimpanzees demonstrates a dose- and exposure-related induction of serum IFN-α, select cytokines/chemokines, and interferon-stimulated genes (ISG) in the peripheral blood and liver. Following oral administration at 0.3 (n=3), and 1 mg/kg (n=3 and n=4), GS-9620 Cmax is 3.6±3.5, 36.8±34.5, and 55.4±81.0 nM, respectively. Peak serum interferon responses occur at 8 h post-dose. The mean peak levels of induced serum IFN-α are 66 and 479 pg/mL at doses of 0.3 and 1 mg/kg, respectively. GS-9620 treatment induces ISG transcripts including ISG15, OAS-1, MX1, IP-10 (CXCL10), and I-TAC (CXCL11) in peripheral blood mononuclear cells (PBMC) at 0.3 mg/kg and in both PBMC and the liver at 1 mg/kg. |